Financial Performance - The company's operating revenue for 2020 was CNY 1,038,636,032.50, representing an increase of 87.26% compared to CNY 554,636,645.87 in 2019 [26]. - The net profit attributable to shareholders for 2020 was CNY 408,046,268.44, a significant increase of 118.57% from CNY 186,686,665.96 in 2019 [26]. - The net profit after deducting non-recurring gains and losses was CNY 402,958,968.71, up 119.45% from CNY 183,618,256.41 in 2019 [26]. - The basic earnings per share for 2020 was CNY 7.77, an increase of 87.23% compared to CNY 4.15 in 2019 [26]. - The total assets at the end of 2020 were CNY 2,147,678,235.61, reflecting a growth of 211.65% from CNY 689,136,081.99 at the end of 2019 [26]. - The net assets attributable to shareholders at the end of 2020 were CNY 1,974,434,296.41, an increase of 243.59% from CNY 574,650,243.31 at the end of 2019 [26]. - The company reported a net cash flow from operating activities of CNY 369,564,379.69, which is a 102.25% increase from CNY 182,729,747.72 in 2019 [26]. - The total revenue for the year 2020 reached CNY 1,038,636,032.50, representing a 87.26% increase compared to CNY 554,636,645.87 in 2019 [65]. - The net profit attributable to the parent company was 408.05 million CNY, with a year-on-year increase of 118.57% [57]. - The company achieved a gross margin of 93.95% in the bioproducts sector, with a slight decrease of 0.22% from the previous year [68]. Dividend Policy - The company plans to distribute a cash dividend of 15 RMB per 10 shares to all shareholders, based on a total of 60,000,000 shares, and will also increase capital by 5 shares for every 10 shares held [7]. - The total cash dividend amount is 90 million CNY, which represents 22.06% of the net profit attributable to ordinary shareholders in the consolidated financial statements for 2020 [135]. - The company has not distributed cash dividends in the years 2018 and 2019, with the 2020 dividend being the first since its public offering [132]. - The cash dividend distribution plan complies with the company's articles of association and dividend management measures [131]. - The total distributable profit for the year is 647,054,507.10 CNY, with the cash dividend accounting for 100% of the profit distribution [131]. Research and Development - The company invested 58.25 million CNY in R&D, marking a 155.66% increase compared to the previous year [57]. - The company launched 10 R&D projects, with several vaccines expected to enter clinical trials in 2021-2022 [60]. - The company has established multiple vaccine research and development platforms and has participated in national projects such as the 863 Program [42]. - The R&D personnel count increased to 53 in 2020, up from 30 in 2019, indicating a focus on enhancing research capabilities [79]. - The company is actively pursuing partnerships for R&D projects with institutions like the Chinese Academy of Sciences and universities [57]. Product and Market Development - The company's core product, the freeze-dried human rabies vaccine (human diploid cells), contributed over 90% of profits during the reporting period [46]. - The rabies vaccine accounted for 96.27% of total revenue, generating CNY 999,942,062.54 in 2020, up from CNY 537,721,664.49 in 2019 [65]. - The company is positioned to benefit from the growing vaccine market in emerging countries, driven by increasing public awareness and supportive policies [47]. - The company expanded its marketing coverage to 1,667 disease control centers and 3,400 vaccination points [57]. - The company is advancing the construction of a second workshop for viral vaccines with an annual capacity of 2 million doses for the freeze-dried human rabies vaccine [57]. Risk Management - The company emphasizes the importance of risk management in new product development, which typically requires 5-10 years for clinical research and regulatory approvals, indicating a high level of uncertainty in achieving expected outcomes [6]. - The company is closely monitoring changes in industry regulations, particularly those related to vaccine production and sales, to mitigate operational risks associated with policy shifts [6]. - The company faces risks from industry policy changes, requiring compliance with new regulations such as the Vaccine Administration Law and Drug Administration Law, which enhance industry standards and oversight [120]. - The company has established a product quality control system and adverse reaction handling system to mitigate risks associated with adverse vaccine reactions, ensuring compliance with relevant laws [120]. Shareholding and Governance - The company has committed to not transferring or managing its shares for 36 months following the public offering, with a lock-up period extending for an additional 2 years under certain conditions [136]. - The company has established a two-year period post-lock-up during which any share reduction must adhere to the issuance price [141]. - The company has implemented strict guidelines for share transfers by its executives to maintain market confidence [141]. - The company has committed to ensuring the stability of control by its actual controller and will not seek to gain control over the company through its shareholding [166]. - The company has made commitments to protect the legitimate rights and interests of minority investors, ensuring transparency and accountability in its operations [166]. Compliance and Legal Matters - The company reported no significant litigation or arbitration matters during the year [174]. - There were no penalties or rectification situations reported during the period [175]. - The company has not engaged in any related party transactions during the reporting period [177][178][180]. - The company has not faced any delisting situations following the annual report disclosure [172]. - The company has not reported any significant accounting policy changes or major accounting error corrections during the reporting period [169].

成都康华生物制品股份有限公司 2021 年第一季度报告 成都康华生物制品股份有限公司 2021 年第一季度报告 公告编号：2021-022 2021 年 4 月 1 成都康华生物制品股份有限公司 2021 年第一季度报告 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季度报告的董事会会议。 公司负责人王清瀚、主管会计工作负责人唐名太及会计机构负责人(会计 主管人员)吴文年声明：保证季度报告中财务报表的真实、准确、完整。 2 成都康华生物制品股份有限公司 2021 年第一季度报告 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|-----------------------------------------|----------|-------------- ...

成都康华生物制品股份有限公司 2020 年第三季度报告全文 成都康华生物制品股份有限公司 2020 年第三季度报告 2020-047 2020 年 10 月 1 成都康华生物制品股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王清瀚、主管会计工作负责人唐名太及会计机构负责人(会计主 管人员)吴文年声明：保证季度报告中财务报表的真实、准确、完整。 2 成都康华生物制品股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------------------------------------|-------------------------|----- ...

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 454,913,998.32, representing a 67.97% increase compared to CNY 270,838,551.93 in the same period last year[27]. - The net profit attributable to shareholders of the listed company reached CNY 182,691,172.79, a significant increase of 115.51% from CNY 84,771,951.56 in the previous year[27]. - The net profit after deducting non-recurring gains and losses was CNY 182,265,864.96, up 116.57% from CNY 84,160,105.95 year-on-year[27]. - The net cash flow from operating activities was CNY 137,148,544.77, reflecting a 140.66% increase compared to CNY 56,989,684.74 in the same period last year[27]. - The basic earnings per share were CNY 4.0598, which is a 115.51% increase from CNY 1.8838 in the previous year[27]. - The total assets at the end of the reporting period amounted to CNY 1,892,548,466.21, a 174.63% increase from CNY 689,136,081.99 at the end of the previous year[27]. - The net assets attributable to shareholders of the listed company were CNY 1,744,647,142.37, showing a 203.60% increase from CNY 574,650,243.31 at the end of the previous year[27]. - The weighted average return on net assets was 27.43%, an increase of 6.76% compared to 20.67% in the previous year[27]. Research and Development - The company has eight major ongoing research projects, including the "human rabies vaccine (human diploid cells) immobilized bioreactor culture process"[37]. - The company has established a research platform for viral vaccines, bacterial vaccines, and genetic engineering, focusing on continuous optimization of existing production processes[45]. - The company is advancing multiple research projects, including the rabies vaccine and tetanus vaccine, with clinical trials expected to commence in 2020-2021[51]. - The company is conducting experimental research on the immune efficacy of existing vaccine products to enhance safety and production processes[86]. - Research and development expenses increased by 226.39% to ¥20,566,974.67 from ¥6,301,410.88 in the previous year, indicating a significant investment in new product development[58]. Market and Sales - The core product, freeze-dried human rabies vaccine (human diploid cells), has seen increased sales due to market demand during the pandemic[37]. - The total sales volume of the ACYW135 meningococcal polysaccharide vaccine was 372,010,000 doses in the first half of 2020, a 79.43% increase from 207,320,000 doses in the first half of 2019[54]. - The sales volume of rabies vaccine reached 3,733,880,000 doses in the first half of 2020, a 70.47% increase from 2,190,410,000 doses in the same period last year[54]. - The marketing network has expanded to cover 1,504 disease control centers, enhancing brand recognition through public education initiatives[50]. Financial Position - The company reported a net increase in cash and cash equivalents of ¥1,059,778,693.33, a 2,661.17% increase compared to ¥38,381,570.39 in the previous year[58]. - The proportion of cash and cash equivalents to total assets rose to 68.77% from 24.11%, attributed to the successful fundraising from the initial public offering[62]. - The company's total liabilities decreased by 2.49% as short-term borrowings were fully repaid during the reporting period[62]. - The total current assets reached ¥1,722,540,581.88, up from ¥577,305,456.74, indicating an increase of approximately 198.5%[163]. - The total non-current liabilities amounted to ¥1,698,245.31, compared to ¥1,418,960.47 in the previous period, indicating an increase of approximately 19.6%[178]. Corporate Governance and Compliance - The company has disclosed potential risks and corresponding countermeasures in its report, which investors should pay attention to[6]. - The company has established a product quality control system and adverse reaction handling system to mitigate risks associated with vaccine quality and adverse events[83]. - The company has not utilized any of the raised funds during the reporting period, with a net amount of raised funds totaling ¥98,097.30[67]. - There were no significant litigation or arbitration matters during the reporting period[96]. - The company has no major related party transactions during the reporting period[99]. Shareholder Information - The company issued 15 million shares at a price of 70.37 RMB per share, raising a total of 1.05555 billion RMB[122]. - After the issuance, the total share capital of the company increased to 60 million shares[125]. - The largest shareholder, Pingtan Yingke Shengdao Investment Partnership, holds 20.60% of the shares, totaling 12,359,880 shares[126]. - The second largest shareholder, Aokang Group Co., Ltd., holds 16.08% of the shares, totaling 9,646,875 shares[126]. - The company has a total of 29,665 common stock shareholders at the end of the reporting period[126]. Future Outlook - The company is actively expanding its vaccine product line, with two new vaccines in preclinical research stages, including a diphtheria genetic engineering vaccine and a rotavirus genetic engineering vaccine[54]. - The company follows a research and development strategy focused on "product upgrades" and "filling domestic gaps," continuously innovating products and processes[86]. - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[91].